Clinical Trials Browser

Has results × Has announcements × Neoplasm Metastasis × Clear all

Melanoma, Neoplasm Metastasis, Neoplasms, Skin Diseases, Skin Neoplasms

NCT02000622 2026-02-13

OlympiAD

Phase 3 Completed

302 enrolled 26 charts 1 FDA

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT05104866 2026-02-04

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Phase 3 Active not recruiting

732 enrolled 22 charts 1 FDA

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04035486 2025-10-10

FLAURA2

Phase 3 Active not recruiting

587 enrolled 44 charts 1 FDA

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Phase 3 Active not recruiting

557 enrolled 22 charts 1 FDA

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04975308 2025-07-11

EMBER-3

Phase 3 Active not recruiting

874 enrolled 29 charts 1 FDA

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03248492 2025-06-26

DESTINY-Breast01

Phase 2 Terminated

253 enrolled 21 charts 1 FDA

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03505710 2025-05-30

DESTINY-Lung01

Phase 2 Terminated

181 enrolled 17 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT02492711 2025-03-17

SOPHIA

Phase 3 Completed

624 enrolled 17 charts 2 FDA

Tumor-Agnostic

Neoplasm Metastasis

NCT02414139 2024-03-20

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Phase 2 Completed

373 enrolled 34 charts 3 FDA

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT01774721 2023-11-14

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Phase 3 Completed

452 enrolled 35 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Clinical Trials

COLUMBUS

OlympiAD

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

FLAURA2

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

EMBER-3

DESTINY-Breast01

DESTINY-Lung01

SOPHIA

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.